Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Other Non-Current Liabilities (2016 - 2025)

Corvus Pharmaceuticals' Other Non-Current Liabilities history spans 6 years, with the latest figure at $3.8 million for Q1 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $3.8 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Mar 2025, changed N/A year-over-year, with the annual reading at $28.9 million for FY2024, N/A changed from the prior year.
  • Other Non-Current Liabilities came in at $3.8 million for Q1 2025, down from $28.9 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $40.0 million in Q3 2024 to a low of $3.8 million in Q1 2025.